Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study

BACKGROUND: While chronic kidney disease (CKD) is common in resistant hypertension (RHTN), prior studies ­evaluating mineralocorticoid receptor antagonists excluded patients with reduced kidney function due to risk of hyperkalemia. AMBER (ClinicalTrials.gov identifier NCT03071263) will evaluate if t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Nephrol
Main Authors: Agarwal, Rajiv, Rossignol, Patrick, Garza, Dahlia, Mayo, Martha R., Warren, Suzette, Arthur, Susan, Romero, Alain, White, William B., Williams, Bryan
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2018
Assuntos:
Original Report: Patient-Oriented, Translational Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6214611/
https://ncbi.nlm.nih.gov/pubmed/30176673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000492622
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados